RE:RE:Question for the CEO, Mr. Moreau @ Algernon Pharmaceuticals To sum up the CEO's answer to the SH question about market valuation...What the CEO basically said is it's his belief the market should be valuing a DMT story about a Phase 1 clinical trial that might start before the end of the year (no definitive commitment), and the latest story about exploring Cancer ($$$$$ very expensive endeavor). Oh and let's not forget, the market should be valuing the IPF and Chronic Cough study that has no end in sight. It's those stories that the m,arket should look to for valuation in 2022 and beyond. Meanwhile, we still have this COVID thing hanging on by a thread - I guess.
BlaineBorg wrote: Please allow me rephase the question: For the past 16 months, the COVID-19 news releases make up 75% of all the news releases targeting a specific disease. That's a ratio of 3 out of every 4 news releases are for COVID-19. Therefore, why would the market think Algernon Pharmaceuticals isn't a "COVID" company?
BlaineBorg wrote: As of March 2020 to the present, here is the percentage of news releases individually targeting COVID-19, IPF & Chronic Cough, DMT, and Cancer.
COVID-19 - 63%
IPF & Chronic Cough - 6%
DMT - 10%
Cancer - Less than 1%
The remaining 20% of news releases targeted financing, webcast announcements, and other shiii.
Here is a portion of what the CEO stated in a SH interview just days ago.
SH: It’s been a busy year for Algernon, and investors are taking notice, yet you’ve had a bit of a roller coaster ride on the markets. What can you tell our investor audience regarding the current valuation of your stock and why you think it’s a good buy right now?
CJM: You know, I've said many times over the last couple of months that Algernon is not a COVID company, but if you sort of look at the stock and the trading, I think the COVID story did consume much of the oxygen in the room and has for the last period of time...
Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke | 2021-06-16 | Investing News | Stockhouse
So here's my question to Mr. Moreau:
If 75% of all news releases the past 16 Months (since March 2020) are targeted to COVID-19, why would the market think Algernon Pharmaceuticals isn't a "COVID" company?
Again, 75% of Algernon's messaging is COVID-19. I mean you can try to flip the script, but the facts remain - Algernon is a COVID-19 company. COVID-19 is what has diluted the company and will continue to dilute the company for the foreseeable future without a partnership/sponsorship deal or data from the IPF/Chronic Cough study. DMT being in 2nd Place as far as "news" may likely take the forefront but without a conclusion to the COVID-19 "story" Algernon remains a COVID-19 company. None of the other stuff, including IPF and Chronic Cough has so far captured the market's attention. Nor do we know when the IPF and Chronic Cough data will become available. COVID-19 is the story. You don't need to know rocket science to know the market awaits EOP2 news.
BB